Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults : a randomized, double-blind, placebo-controlled pilot study Alicia L. Danforth, Charles S. Grob, Christopher Struble, Allison A. Feduccia, Nick Walker, Lisa Jerome, Berra Yazar-Klosinski & Amy Emerson Psychopharmacology, 2018, https://doi.org/10.1007/s00213-018-5010-9 Abstract Rationale : Standard therapeutic approaches to reduce social anxiety in autistic adults have limited effectiveness. Since 3,4- methylenedioxymethamphetamine (MDMA)-assisted psychotherapy shows promise as a treatment for other anxiety disorders, a blinded, placebo-controlled pilot study was conducted. Objectives : To explore feasibility and safety ofMDMA-assisted psychotherapy for reduction of social fear and avoidance that are common in the autistic population. Methods : Autistic adults with marked to [...]
Lire la suitePilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Charles S. Grob, Alicia L. Danforth, Gurpreet S. Chopra, Marycie Hagerty, Charles R. McKay, Adam L. Halberstadt, George R. Greer Archive of General Psychiatry, 2010, 68, (1), 71–78 doi: 10.1001/archgenpsychiatry.2010.116 Context : Researchers conducted extensive investigations of hallucinogens in the 1950s and 1960s. By the early 1970s, however, political and cultural pressures forced the cessation of all projects. This investigation reexamines a potentially promising clinical application of hallucinogens in the treatment of anxiety reactive to advanced-stage cancer. Objective : To explore the safety and efficacy of psilocybin in patients with advanced-stage cancer and [...]
Lire la suiteDeveloping Guidelines and Competencies for the Training of Psychedelic Therapists Janis Phelps Journal of Humanistic Psychology, 2017, 1–38 DOI: 10.1177/0022167817711304 Abstract Research since the 1950s has shown that psychedelic-assisted psychotherapy has had significant positive effects in reductions of specific clinical symptoms and increases in quality of life as measured on a variety of indices. The intensity of focus on evidence-based outcomes, however, has resulted in a paucity of active discussions and research on the core competencies of the therapists themselves. The context of the history of psychedelic research reveals how this neglect of therapist variables occurred. With current discussions of Phase 3 and expanded access [...]
Lire la suiteWelcome letter | Program | Registration | Abstract Submission Abstracts topics Phytocannabinoid study – strains, chemovars, entourage and molecules. Pharamacokinetics and pharmacodynamics of cannabinoids Prediction of response to cannabinoid treatment Clinical trials targeting Pain, GI Disorders, Palliative Care, Psychiatry and Neurological disorders New designs for cannabis clinical trials (including pragmatic trials and n=1) Clinical Registries Observational / Epidemiological studies: findings, interpretations, plans Phase 2/3/4 study findings and designs (including special populations) Meta- and composite- analyses: findings and methodology Regulatory, licensing, and development programme issues and plans Cannabinoid trial best conduct including GCP and site training Assessing safety of cannabinoid medications Innovative [...]
Lire la suiteOpioïdes : le cannabidiol pour réduire la dépendance ? Le cannabidiol (CBD) réduit le craving et l'anxiété chez les personnes ayant des antécédents d'abus d'héroïne/opioïdes, suggérant un rôle possible du cannabis ou de son agent le cannabidiol dans la réduction de la dépendance aux opioïdes. C’est la conclusion de cette étude réalisée à l’Icahn School of Medicine du Mont Sinaï (New York), présentée dans l'American Journal of Psychiatry. L'étude confirme également les effets anti-stress du CBD avec une baisse de la fréquence cardiaque et du taux de cortisol induites par les stimuli de drogues. La grande disponibilité des opioïdes sur prescription ces [...]
Lire la suiteHuman psychopharmacology and dose-effects of salvinorin A, a kappa-opioid agonist hallucinogen present in the plant Salvia divinorum Matthew W. Johnson, Katherine A. MacLean, Chad J. Reissig, Thomas E. Prisinzano and Roland R. Griffiths Drug and Alcohol Dependence, 2011, 115, (1-2), 150–155. doi: 10.1016/j.drugalcdep.2010.11.005 Abstract Salvinorin A is a potent, selective nonnitrogenous kappa opioid agonist and the known psychoactive constituent of Salvia divinorum, a member of the mint family that has been used for centuries by Mazatec shamans of Mexico for divination and spiritual healing. Salvia divinorum has over the last several years gained increased popularity as a recreational drug. This is a double-blind, placebo controlled [...]
Lire la suitePsychedelic-Assisted Psychotherapy : A Paradigm Shift in Psychiatric Research and Development Eduardo Ekman Schenberg Frontiers in Pharmacology, 2018, Volume 9, Article 733, 1-11 doi: 10.3389/fphar.2018.00733 Abstract Mental disorders are rising while development of novel psychiatric medications is declining. This stall in innovation has also been linked with intense debates on the current diagnostics and explanations for mental disorders, together constituting a paradigmatic crisis. A radical innovation is psychedelic-assisted psychotherapy (PAP): professionally supervised use of ketamine, MDMA, psilocybin, LSD and ibogaine as part of elaborated psychotherapy programs. Clinical results so far have shown safety and efficacy, even for “treatment resistant” conditions, and thus deserve increasing attention [...]
Lire la suiteLong-term follow-up of psilocybin-facilitated smoking cessation Johnson M.W., Garcia-Romeu A., Griffiths R.R. The American Journal of Drug and Alcohol Abuse, 2017, 43, (1), 55–60 http://dx.doi.org/10.3109/00952990.2016.1170135 Abstract Background : A recent open-label pilot study (N = 15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist, psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone. Objectives : To assess long-term effects of a psilocybin-facilitated smoking cessation program at ≥12 months after psilocybin administration. Methods : The present [...]
Lire la suitePsychedelic microdosing benefits and challenges : an empirical codebook Thomas Anderson, Rotem Petranker2, Adam Christopher, Daniel Rosenbaum, Cory Weissman, Le-Anh Dinh-Williams, Katrina Hui and Emma Hapke Harm Reduction Journal, 2019, 16, 43, 1-10 https://doi.org/10.1186/s12954-019-0308-4 Abstract Background : Microdosing psychedelics is the practice of consuming very low, sub-hallucinogenic doses of a psychedelic substance, such as lysergic acid diethylamide (LSD) or psilocybin-containing mushrooms. According to media reports, microdosing has grown in popularity, yet the scientific literature contains minimal research on this practice. There has been limited reporting on adverse events associated with microdosing, and the experiences of microdosers in community samples have not been categorized. Methods : In the [...]
Lire la suiteEfficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study Carla M. Canuso, M.D., Jaskaran B. Singh, M.D., Maggie Fedgchin, Pharm.D., Larry Alphs, M.D., Ph.D., Rosanne Lane, M.A.S., Pilar Lim, Ph.D., Christine Pinter, M.S., David Hough, M.D., Gerard Sanacora, M.D., Ph.D., Husseini Manji, M.D., Wayne C. Drevets, M.D. American Journal of Psychiatry, 2018, 175, 620–630 doi: 10.1176/appi.ajp.2018.17060720 Objective : The authors compared the efficacy of standardof- care treatment plus intranasal esketamine or placebo for rapid reduction of symptoms of major depression, including suicidality, among [...]
Lire la suite